BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.
BiVictriX Therapeutics Limited
BVX:JPJ · MBF
Company Details
The instrument
The company
Listing & trading
Contact
Share Registrars Limited (Registrar)
Share Registrars Limited
The Courtyard
17 West Street
Farnham
Surrey GU9 7DR
Recent Trades
| Date | Quantity | Mid Price |
Type
Legend: AT - Automatic Trade AX - Agency Cross PI - Primary Issuance NT - Negotiated Trade UT - Uncrossing Trade |
|---|---|---|---|
| 04/02/2025 | 3,763 | 10.50 | |
| 18/10/2024 | 48,282 | 10.50 | |
| 30/09/2024 | 50,000 | 11.50 | |
| 16/09/2024 | 100,000 | 11.00 | |
| 16/09/2024 | 150,000 | 11.00 |
Management Team
Dr Michael Kauffman
Non-Executive Chairman
Tiffany Thorn
Chief Executive Officer
Petter Veiby
Non-Executive Director
Documents & Downloads
Latest News
BiVictriX Therapeutics Strengthens Board with US-Facing Appointment
11 Aug 2025
BiVictriX Therapeutics – BVX002 Data Update
26 Jun 2025
Business Update – BVX
20 Jun 2025
BiVictriX Therapeutics Limited shares now trading on JP Jenkins
11 Sep 2024
Proposed voluntary cancellation of admission of Ordinary Shares to trading on AIM
12 Aug 2024
Interim Results for the Six Months Ended 30 June 2024
01 Aug 2024
